文献速递胸部肿瘤

血液蛋白标志物组合助力不确定肺结节分类

Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
PubMed 文献 · J Thorac Oncol · 2020-10-31

研究评估四蛋白标志物组合在不确定肺结节良恶性鉴别中的效用,在匹兹堡大学医学中心和德克萨斯大学西南医学中心两个病例对照队列中,该组合较仅基于结节大小的模型改善了肺癌风险预测,并在高特异性下显著提高敏感性。

要点

  • 四蛋白标志物组合在不确定肺结节中可区分良恶性。
  • 该组合较仅基于结节大小的模型改善肺癌风险预测。
  • 加入标志物组合后在高特异性下大幅提高敏感性。

核心结论

  • 四标志物蛋白组合此前已验证可改善肺癌风险预测,本研究显示其还能区分不确定肺结节的良恶性。
  • 该组合在高特异性下提高敏感性的表现,提示其可用于评估不确定结节的恶性可能性。

研究设计与样本

  • 研究采用两个病例对照队列,分别来自匹兹堡大学医学中心和德克萨斯大学西南医学中心,对象为不确定肺结节患者。
  • 对每个队列的匹配病例和对照样本,使用此前验证过的多重酶联免疫分析法检测四蛋白标志物组合。

主要发现

  • 在两个队列中,标志物组合对肺癌风险的预测均优于仅基于结节大小的模型。
  • 将标志物组合加入结节大小后,两个队列在高特异性下的敏感性均大幅提高。

临床怎么用

  • 对于影像学不确定的肺结节,可考虑检测四蛋白标志物组合以辅助评估恶性风险。
  • 该组合在高特异性下提高敏感性,可能有助于识别需进一步检查或可安全随访的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: The workup and longitudinal monitoring for subjects presenting with pulmonary nodules is a pressing clinical problem. A blood-based biomarker panel potentially has utility for identifying subjects at higher risk for harboring a malignant nodule for whom additional workup would be indicated or subjects at reduced risk for whom imaging-based follow-up would be indicated. OBJECTIVES: To assess whether a previously described four-protein biomarker panel, reported to improve assessment of lung cancer risk compared with a smoking-based lung cancer risk model, can provide discrimination between benign and malignant indeterminate pulmonary nodules. METHODS: A previously validated multiplex enzyme-linked immunoassay was performed on matched case and control samples from each cohort. MEASUREMENTS: The biomarker panel was tested in two case-control cohorts of patients presenting with indeterminate pulmonary nodules at the University of Pittsburgh Medical Center and the University of Texas Southwestern. MAIN RESULTS: In both cohorts, the biomarker panel resulted in improved prediction of lung cancer risk over a model on the basis of nodule size alone. Of particular note, the addition of the marker panel to nodule size greatly improved sensitivity at a high specificity in both cohorts. CONCLUSIONS: A four-marker biomarker panel, previously validated to improve lung cancer risk prediction, was found to also have utility in distinguishing benign from malignant indeterminate pulmonary nodules. Its performance in improving sensitivity at a high specificity indicates potential utility of the marker panel in assessing likelihood of malignancy in otherwise indeterminate nodules.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ostrin EJ, Bantis LE, Wilson DO, et al. Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. J Thorac Oncol. 2020. PMID: 33137463. doi:10.1016/j.jtho.2020.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。